Remibrutinib longitudinal UAS7

This is the first plotted pass from the remibrutinib sponsor-portal extraction layer.

What this page shows

• Only explicit numeric values captured from the current local source stack
• No hand-read curve guessing
• REMIX-1 and REMIX-2 shown separately where the source allowed it
• Week 52 is currently shown only where explicit pooled values were available

Plot 1: Derived mean UAS7 over time

This figure uses explicit baseline UAS7 values plus explicit change-from-baseline values extracted from the ACAAI 2024 early symptom improvement poster.

Plot 2: UAS7 ≤ 6 response over time

This figure uses explicit responder-rate values extracted from the EADV 2024 52-week oral presentation.

Week 52 pooled landmarks

This pooled week 52 callout comes from the GUF/UCARE 2024 band-shift poster.

Current takeaways

• Remibrutinib separates from placebo very early, with visible UAS7 improvement by week 1 in both REMIX studies.
• The main explicit numeric sponsor-portal backbone now covers weeks 0, 1, 2, 4, 12, and 24 for UAS7 trajectory.
• By the current pooled week 52 landmark layer, 35.1% of remibrutinib-treated patients reached UAS7 = 0, while only 8.1% remained in the severe UAS7 band.

Current gaps

• Exact week 52 mean UAS7 change-from-baseline is not yet plotted because it is still graphical in the current local extraction.
• Exact per-trial week 52 UAS7 ≤ 6 values are not yet extracted numerically.
• Placebo-to-remibrutinib switch-arm trajectory is still present mainly as figure content rather than clean tabulated points.

Local evidence files

• Dataset: data/remibrutinib_longitudinal_uas7.json
• Notes: data/remibrutinib_longitudinal_uas7_notes.md
• Source wrappers:
• raw/sponsors/btk/remibrutinib/acaai-2024-early-symptom-improvement-poster.md
• raw/sponsors/btk/remibrutinib/eadv-2024-early-and-long-term-efficacy-oral.md
• raw/sponsors/btk/remibrutinib/guf-2024-disease-activity-band-shift-52wk-poster.md